Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
- 1 April 2011
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (10), 1236-1238
- https://doi.org/10.1200/jco.2010.31.6877
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization ArrayClinical Cancer Research, 2009
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling studyThe Lancet Oncology, 2007
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal CancerCancer Research, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002